
  
    
      
        Background_NNP
        Infection_NNP with_IN the_DT hepatitis_NNP C_NNP virus_NN (_( HCV_NNP )_) occurs_VBZ
        primarily_RB through_IN percutaneous_JJ exposure_NN to_TO contaminated_JJ
        blood_NN or_CC blood_NN products_NNS ._. Unlike_IN most_JJS other_JJ viral_JJ hepatitis_NN
        infections_NNS that_WDT tend_VBP to_TO be_VB acute_JJ ,_, hepatitis_NNP C_NNP infections_NNS
        are_VBP often_RB chronic_JJ and_CC persist_VB for_IN decades_NNS [_NN 1_CD 2_CD 3_CD ]_NN ._. The_DT
        long-term_JJ sequelae_NN of_IN chronic_JJ HCV_NNP infections_NNS include_VBP
        increased_VBN risks_NNS of_IN liver_NN cirrhosis_NNS and_CC hepatocellular_NN
        carcinoma_NN [_NN 4_CD 5_CD ]_NN ._.
        HCV_NNP infection_NN is_VBZ a_DT major_JJ public_JJ health_NN problem_NN in_IN Egypt_NNP
        [_NN 6_CD 7_CD 8_CD ]_NN ._. Blood_NNP bank_NN and_CC community-based_JJ surveys_NNS
        conducted_VBN in_IN Egypt_NNP have_VBP reported_VBN sero-prevalence_JJ rates_NNS of_IN
        HCV_NNP to_TO be_VB as_RB high_JJ as_IN 40_CD %_NN in_IN some_DT parts_NNS of_IN the_DT country_NN [_NN 9_CD
        10_CD 11_CD 12_CD ]_NN ._. These_DT rates_NNS are_VBP substantially_RB higher_JJR in_IN the_DT
        Nile_NNP Delta_NNP region_NN compared_VBN with_IN the_DT rest_NN of_IN the_DT country_NN [_NN
        13_CD ]_NN ._. Schistosomiasis_NNP is_VBZ a_DT parasitic_JJ infection_NN transmitted_VBD
        to_TO humans_NNS from_IN snails_NNS that_WDT harbor_NN the_DT parasite_NN ._. Most_JJS rural_JJ
        and_CC peri-urban_JJ areas_NNS located_VBN in_IN the_DT Nile_NNP Delta_NNP are_VBP in_IN close_JJ
        proximity_NN to_TO the_DT distributaries_NNS of_IN the_DT Nile_NNP River_NNP or_CC
        irrigation_NN canals_NNS drawn_VBN from_IN the_DT Nile_NNP ._. These_DT slow_JJ flowing_VBG
        waters_NNS are_VBP infested_JJ with_IN snails_NNS that_WDT serve_VBP as_IN the_DT vector_NN
        for_IN the_DT schistosomal_NN parasite_NN ._. Schistosomiasis_NNP infections_NNS ,_,
        in_IN addition_NN to_TO HCV_NNP are_VBP hyperendemic_JJ in_IN the_DT Nile_NNP Delta_NNP
        region_NN [_NN 14_CD ]_NN ._.
        In_IN the_DT 1960_CD s_VBZ ,_, 1970_CD s_VBZ and_CC early_JJ 1980_CD s_VBZ ,_, mass_NN campaigns_NNS were_VBD
        conducted_VBN to_TO treat_VB schistosomiasis_NNS infections_NNS in_IN these_DT
        areas_NNS ,_, during_IN which_WDT individuals_NNS older_JJR than_IN 5_CD years_NNS of_IN age_NN
        were_VBD treated_VBN with_IN tartar_NN emetic_JJ injections_NNS [_NN 15_CD ]_NN ._.
        Sero-surveys_NNP conducted_VBD in_IN the_DT 1990_CD 's_POS in_IN Egypt_NNP have_VBP reported_VBN
        positive_JJ associations_NNS between_IN HCV_NNP infections_NNS and_CC a_DT history_NN
        of_IN schistosomiasis_NNS or_CC a_DT history_NN of_IN having_VBG received_VBN
        injections_NNS for_IN the_DT treatment_NN of_IN schistosomiasis_NNS [_NN 9_CD 12_CD 13_CD
        16_CD ]_NN ._. Based_VBN on_IN this_DT evidence_NN ,_, the_DT studies_NNS suggest_VBP that_IN
        inadequately_RB sterilized_VBN needles_NNS and_CC syringes_NNS used_VBN during_IN
        the_DT campaign_NN were_VBD probable_JJ causes_NNS for_IN transmission_NN of_IN HCV_NNP
        in_IN the_DT region_NN ._.
        Since_IN all_PDT the_DT studies_NNS were_VBD conducted_VBN as_IN cross-sectional_JJ
        surveys_NNS ,_, it_PRP is_VBZ not_RB possible_JJ to_TO know_VB whether_IN the_DT HCV_NNP
        infections_NNS were_VBD pre-existing_JJ at_IN the_DT time_NN of_IN the_DT treatment_NN
        campaigns_NNS or_CC whether_IN they_PRP were_VBD incident_NN infections_NNS as_IN a_DT
        consequence_NN of_IN the_DT campaigns_NNS ._. The_DT studies_NNS have_VBP also_RB
        reported_VBN low_JJ prevalence_NN rates_NNS in_IN the_DT younger_JJR age_NN groups_NNS and_CC
        high_JJ prevalence_NN rates_NNS for_IN the_DT older_JJR ages_NNS suggesting_VBG that_WDT
        individuals_NNS infected_VBN between_IN the_DT 1960_CD 's_POS to_TO the_DT early_JJ 80_CD 's_POS
        are_NN now_RB older_JJR and_CC more_RBR likely_JJ to_TO be_VB sero-positive_JJ compared_VBN
        to_TO those_DT born_VBN after_IN the_DT campaigns_NNS ._. A_DT limitation_NN of_IN most_JJS of_IN
        the_DT published_VBN studies_NNS is_VBZ the_DT implicit_JJ assumption_NN in_IN their_PRP$
        analyses_NNS that_IN all_PDT the_DT individuals_NNS in_IN the_DT survey_NN are_VBP
        independent_JJ of_IN each_DT other_JJ and_CC that_IN infection_NN rates_NNS are_VBP
        uniformly_RB distributed_VBN both_DT within_IN and_CC across_IN all_DT households_NNS
        in_IN the_DT community_NN ._. If_IN the_DT suggested_VBN nosocomial_NN mechanism_NN of_IN
        transmission_NN were_VBD true_JJ ,_, the_DT assumption_NN that_IN infection_NN rates_NNS
        are_VBP uniformly_RB distributed_VBN would_MD not_RB be_VB valid_JJ ,_, because_IN HCV_NNP
        infections_NNS will_MD tend_VB to_TO cluster_NN within_IN households_NNS that_WDT
        participated_VBD in_IN the_DT campaign_NN compared_VBN to_TO households_NNS that_WDT
        did_VBD not_RB ._. The_DT uniform_NN distribution_NN assumption_NN is_VBZ further_RBR
        complicated_VBN by_IN the_DT existence_NN of_IN sub-groups_JJ of_IN high_JJ risk_NN and_CC
        low_JJ risk_NN individuals_NNS within_IN each_DT house_NN based_VBN on_IN their_PRP$ date_NN
        of_IN birth_NN ._. If_IN a_DT household_NN participated_VBD in_IN the_DT campaign_NN and_CC
        has_VBZ an_DT infected_JJ member_NN ,_, there_EX is_VBZ a_DT greater_JJR likelihood_NN that_IN
        another_DT member_NN who_WP resided_VBN in_IN the_DT same_JJ house_NN at_IN the_DT time_NN of_IN
        the_DT campaign_NN will_MD be_VB infected_JJ ,_, but_CC a_DT low_JJ likelihood_NN that_IN an_DT
        individual_JJ born_VBN within_IN the_DT same_JJ house_NN after_IN the_DT campaign_NN
        period_NN will_MD be_VB infected_JJ ._.
        We_PRP postulate_NN that_IN an_DT entire_JJ household_NN was_VBD more_RBR likely_JJ to_TO
        have_VB participated_VBN in_IN the_DT campaign_NN if_IN at_IN least_JJS one_CD member_NN of_IN
        the_DT household_NN had_VBD a_DT history_NN of_IN schistosomiasis_NNS and_CC received_VBD
        treatment_NN by_IN injections_NNS ,_, compared_VBN to_TO houses_NNS in_IN which_WDT no_DT
        member_NN reported_VBD a_DT past_JJ history_NN and_CC parenteral_NN treatment_NN for_IN
        schistosomiasis_NNS ._. Based_VBN on_IN this_DT premise_NN ,_, we_PRP would_MD expect_VB
        clustering_VBG of_IN HCV_NNP infection_NN in_IN households_NNS in_IN which_WDT one_CD or_CC
        more_JJR members_NNS reported_VBD having_VBG received_VBN parenteral_NN treatment_NN
        for_IN schistosomiasis_NNS ,_, if_IN the_DT underlying_VBG reason_NN for_IN the_DT
        spread_NN of_IN HCV_NNP infection_NN was_VBD in_IN fact_NN attributable_JJ to_TO the_DT
        treatment_NN campaign_NN ._.
        Using_VBG the_DT HCV_NNP infection_NN status_NN of_IN individuals_NNS
        participating_VBG in_IN a_DT community_NN based_VBD sero-survey_JJ conducted_VBN in_IN
        the_DT Nile_NNP delta_NN of_IN rural_JJ Egypt_NNP ,_, we_PRP tested_VBD the_DT following_VBG
        hypotheses_NNS to_TO assess_VB if_IN the_DT schistosomiasis_NNS treatment_NN
        campaigns_NNS were_VBD associated_VBN with_IN transmission_NN of_IN HCV_NNP :_:
        i_NNP )_) Participation_NNP by_IN village_NN residents_NNS in_IN the_DT
        schistosomiasis_NNS treatment_NN campaigns_NNS were_VBD likely_JJ to_TO cluster_NN
        within_IN houses_NNS ,_, with_IN members_NNS of_IN a_DT house_NN more_RBR likely_JJ to_TO
        participate_VB in_IN the_DT campaign_NN if_IN at_IN least_JJS one_CD member_NN
        participated_VBD ._.
        ii_NN )_) Clustering_NNP of_IN HCV_NNP infections_NNS within_IN houses_NNS is_VBZ more_RBR
        likely_JJ among_IN houses_NNS that_WDT participated_VBD in_IN the_DT treatment_NN
        campaigns_NNS compared_VBN to_TO those_DT that_WDT did_VBD not_RB ._.
      
      
        Methods_NNP
        
          Site_NNP
          The_DT study_NN was_VBD conducted_VBN in_IN Kalama_NNP ,_, a_DT semi-urban_JJ area_NN
          in_IN Qalyub_NNP District_NNP of_IN the_DT Qualyabia_NNP Governorate_NNP ._. The_DT
          village_NN is_VBZ located_VBN on_IN the_DT south-east_JJ edge_NN of_IN the_DT Nile_NNP
          River_NNP delta_NN ,_, approximately_RB 19_CD km_NN north_RB of_IN Heliopolis_NNP ,_,
          Cairo_NNP ,_, Egypt_NNP ._. Irrigated_NNP farmlands_NNS and_CC canals_NNS surround_VBP the_DT
          village_NN ,_, a_DT feature_NN typical_JJ of_IN the_DT Nile_NNP delta_NN ._. The_DT village_NN
          has_VBZ a_DT population_NN of_IN approximately_RB 17_CD 000_CD residents_NNS living_VBG
          in_IN about_IN 2400_CD houses_NNS ._. Agriculture_NNP is_VBZ the_DT primary_JJ
          occupation_NN ._. Residents_NNS live_VBP in_IN small_JJ single_JJ story_NN homes_NNS
          either_CC as_IN single_JJ nuclear_JJ families_NNS or_CC extended_VBN families_NNS
          with_IN multiple_JJ related_VBN nuclear_JJ families_NNS residing_VBG within_IN
          the_DT same_JJ house_NN ._. The_DT median_JJ household_NN size_NN was_VBD 7_CD persons_NNS
          at_IN the_DT time_NN of_IN the_DT study_NN ._.
        
        
          Population_NNP and_CC sero-survey_JJ
          Details_NNS of_IN the_DT study_NN have_VBP been_VBN described_VBN elsewhere_RB [_NN
          16_CD ]_NN ._. Briefly_NNP ,_, after_IN conducting_VBG a_DT census_NN in_IN December_NNP
          1994_CD ,_, the_DT village_NN was_VBD divided_VBN into_IN 12_CD geographic_JJ sectors_NNS ._.
          Every_DT 15_CD thhouse_NN was_VBD then_RB systematically_RB sampled_VBN for_IN
          participation_NN in_IN a_DT sero-survey_JJ ._. Of_IN a_DT total_NN of_IN 172_CD sampled_VBN
          houses_NNS ,_, 168_CD (_( 98_CD %_NN )_) household_NN heads_VBZ agreed_VBN to_TO participate_VB ._.
          Between_IN January_NNP and_CC June_NNP 1995_CD ,_, after_IN obtaining_VBG written_VBN
          informed_VBN consent_NN ,_, we_PRP conducted_VBD a_DT sero-survey_JJ and_CC
          administered_VBN a_DT questionnaire_NN to_TO the_DT study_NN participants_NNS ,_,
          soliciting_VBG medical_JJ and_CC behavioral_JJ risk_NN factors_NNS for_IN liver_NN
          disease_NN ._. History_NN of_IN schistosomiasis_NNS was_VBD obtained_VBN by_IN
          interview_NN in_IN which_WDT participants_NNS were_VBD asked_VBN whether_IN they_PRP
          had_VBD ever_RB received_VBN a_DT diagnosis_NN of_IN schistosomiasis_NNS ._.
          Regardless_RB of_IN their_PRP$ histories_NNS ,_, all_DT participants_NNS were_VBD
          further_RBR queried_VBN about_IN past_JJ treatment_NN for_IN schistosomiasis_NNS
          and_CC whether_IN the_DT treatment_NN was_VBD with_IN oral_JJ drugs_NNS ,_, injections_NNS
          or_CC both_DT ._. Approximately_RB 7_CD ml_NN of_IN blood_NN was_VBD then_RB obtained_VBN
          via_IN a_DT venipuncture_NN from_IN each_DT participant_NN ._. Persons_NNP under_IN
          10_CD years_NNS of_IN age_NN were_VBD excluded_VBN from_IN the_DT sero-survey_JJ
          because_IN earlier_JJR work_NN in_IN Kalama_NNP demonstrated_VBD HCV_NNP infection_NN
          to_TO be_VB rare_JJ in_IN this_DT age_NN group_NN [_NN 12_CD ]_NN ._. Baseline_NNP
          socio-demographic_JJ information_NN was_VBD collected_VBN at_IN the_DT time_NN
          of_IN the_DT census_NN ._. Household_NNP socio-economic_JJ status_NN was_VBD
          classified_VBN as_IN high_JJ ,_, medium_NN or_CC low_NN according_VBG to_TO a_DT locally_RB
          developed_VBN scale_NN ._. Details_NNS of_IN the_DT laboratory_NN methods_NNS used_VBN
          to_TO detect_VB anti-_NN HCV_NNP antibodies_NNS have_VBP been_VBN described_VBN
          elsewhere_RB [_NN 16_CD ]_NN ._. Briefly_NNP ,_, serum_NN from_IN the_DT blood_NN samples_NNS
          was_VBD screened_VBD for_IN anti-_NN HCV_NNP antibodies_NNS by_IN EIA_NNP (_( Abbot_NNP
          Laboratories_NNPS )_) ._. All_DT EIA-reactive_NNP sera_NN were_VBD evaluated_VBN with_IN
          either_DT the_DT second_JJ or_CC third_JJ generation_NN recombinant_JJ
          immunoblot_NN assays_NNS (_( Chiron_NNP Corporation_NNP )_) as_IN confirmatory_NN
          tests_NNS ._. Positive_JJ results_NNS by_IN either_DT of_IN the_DT immunoblot_NN
          assays_NNS were_VBD considered_VBN to_TO be_VB HCV_NNP positive_JJ (_( positive_JJ for_IN
          anti-_NN HCV_NNP antibodies_NNS )_) ._.
        
        
          Statistical_NNP methods_NNS
          For_IN baseline_NN comparisons_NNS of_IN the_DT HCV_NNP positive_JJ and_CC
          negative_JJ individuals_NNS ,_, we_PRP used_VBD the_DT chi-square_JJ test_NN (_( or_CC
          Fisher_NNP 's_POS Exact_JJ test_NN when_WRB there_EX was_VBD sparse_NN data_NNS )_) for_IN
          categorical_JJ variables_NNS ._. For_IN dimensional_NN variables_NNS ,_, the_DT
          t-test_JJ was_VBD used_VBN to_TO compare_VB the_DT two_CD groups_NNS when_WRB the_DT data_NNS
          was_VBD normally_RB distributed_VBN ,_, and_CC the_DT Mann-_NNP Whitney-_NNP U_NNP test_NN ,_,
          when_WRB assumptions_NNS of_IN normality_NN were_VBD not_RB met_VBN ._.
          To_TO test_VB for_IN intra-_NN and_CC inter-class_JJ clustering_VBG of_IN HCV_NNP
          infections_NNS ,_, we_PRP used_VBD a_DT modified_VBN formulation_NN of_IN the_DT
          Generalized_NNP Estimating_VBG Equations_NNP (_( GEE_NNP )_) ._. The_DT original_JJ
          formulation_NN of_IN GEE_NNP also_RB referred_VBD to_TO as_IN GEE_NNP 1_CD [_NN 17_CD ]_NN is_VBZ
          used_VBN in_IN the_DT analysis_NN of_IN correlated_JJ data_NNS in_IN which_WDT
          clustering_VBG is_VBZ treated_VBN as_IN a_DT nuisance_JJ factor_NN that_WDT needs_VBZ to_TO
          be_VB taken_VBN into_IN account_NN at_IN the_DT analysis_NN stage_NN ._. This_DT
          approach_NN uses_VBZ a_DT working_VBG correlation_NN matrix_NN to_TO model_VB the_DT
          correlation_NN between_IN the_DT repeated_VBN or_CC related_VBN observations_NNS
          for_IN an_DT individual_JJ or_CC a_DT cluster_NN while_IN simultaneously_RB
          adjusting_VBG for_IN covariates_NNS in_IN a_DT generalized_JJ linear_JJ model_NN ._.
          With_IN the_DT new_JJ formulation_NN ,_, also_RB referred_VBD to_TO as_IN GEE_NNP 2_CD or_CC
          Alternating_NNP Logistic_NNP Regression_NNP (_( ALR_NNP )_) ,_, clustering_VBG can_MD be_VB
          treated_VBN as_IN a_DT parameter_NN of_IN interest_NN on_IN which_WDT we_PRP can_MD
          perform_VB hypothesis_NNS testing_NN [_NN 18_CD 19_CD 20_CD ]_NN ._. Instead_RB of_IN
          specifying_VBG a_DT correlation_NN matrix_NN ,_, an_DT OR_NNP is_VBZ computed_JJ for_IN
          each_DT cluster_NN in_IN this_DT approach_NN to_TO detect_VB clustering_VBG among_IN
          related_VBN observations_NNS ._. Since_IN the_DT outcome_NN of_IN our_PRP$ study_NN is_VBZ
          binary_JJ (_( HCV_NNP positive_JJ or_CC negative_JJ )_) ,_, we_PRP describe_VBP the_DT
          approach_NN for_IN binary_JJ outcomes_NNS ._.
          For_IN a_DT family_NN of_IN size_NN n_NN ,_, if_IN Y_NNP 
          j_NN is_VBZ the_DT HCV_NNP status_NN (_( 0_CD =_SYM negative_JJ ,_, 1_CD =_SYM
          positive_JJ )_) of_IN the_DT j_NN thindividual_NN ,_, we_PRP define_VB
          log_VB [_NN Pr_NNP (_( Y_NNP 
          j_NN =_SYM 1_LS )_) /_NN Pr_NNP (_( Y_NNP 
          j_NN =_SYM 0_CD )_) ]_NN =_SYM β_NN 
          0_CD +_NN β_NN 
          1_CD x_SYM 
          1_CD j_NN +_NN β_NN 
          2_CD x_SYM 
          2_CD j_NN +_NN ._. ._. ._. ._. ._. ._. +_NN +_NN β_NN 
          m_NN x_SYM 
          mj_NN (_( 1_LS )_)
          where_WRB the_DT x_SYM 's_POS are_NN m_NN covariates_NNS for_IN the_DT j_NN thindividual_NN ._.
          For_IN most_JJS analyses_NNS ,_, the_DT x_SYM 's_POS are_NN variables_NNS that_WDT describe_VBP
          the_DT baseline_NN characteristics_NNS or_CC are_VBP confounding_VBG
          variables_NNS ._. These_DT variables_NNS could_MD be_VB specific_JJ to_TO the_DT j_NN
          thindividual_NN (_( such_JJ as_IN age_NN and_CC gender_NN )_) or_CC could_MD be_VB common_JJ
          for_IN the_DT entire_JJ family_NN (_( e_SYM ._. g_SYM ._. race_NN or_CC socio-economic_JJ status_NN
          of_IN the_DT family_NN )_) ._. The_DT β_NN 's_POS are_NN the_DT regression_NN parameters_NNS to_TO
          be_VB estimated_VBN ._. We_PRP next_JJ define_VB the_DT odds_NNS ratio_NN (_( OR_NNP )_) between_IN
          the_DT j_NN thand_NN k_NN thmembers_NNS of_IN the_DT family_NN as_IN
          
          The_DT odds_NNS ratio_NN is_VBZ a_DT commonly_RB used_VBN measure_NN of_IN
          association_NN for_IN categorical_JJ variables_NNS and_CC assumes_VBZ the_DT
          values_NNS between_IN zero_CD and_CC infinity_NN ._. An_DT odds_NNS ratio_NN equal_JJ to_TO
          one_CD suggests_VBZ the_DT lack_NN of_IN an_DT association_NN between_IN
          individuals_NNS ._. In_IN equation_NN (_( 2_LS )_) ,_, an_DT OR_NNP =_SYM 1_CD for_IN each_DT of_IN the_DT 
          N_NNP C_NNP 
          2_CD (_( number_NN of_IN ways_NNS in_IN which_WDT we_PRP can_MD
          select_VB 2_CD out_IN of_IN N_NNP )_) pairs_NNS of_IN members_NNS within_IN a_DT house_NN
          indicates_VBZ the_DT absence_NN of_IN clustering_VBG of_IN disease_NN within_IN the_DT
          family_NN ._. On_IN the_DT other_JJ hand_NN ,_, an_DT odds_NNS ratio_NN greater_JJR than_IN one_PRP
          will_MD indicate_VB clustering_VBG of_IN disease_NN within_IN the_DT families_NNS ._.
          It_PRP should_MD be_VB noted_VBN that_IN the_DT OR_NNP defined_VBD in_IN (_( 2_LS )_) is_VBZ not_RB the_DT
          same_JJ OR_NNP that_IN one_CD conventionally_RB uses_VBZ to_TO measure_VB the_DT
          association_NN between_IN exposure_NN and_CC disease_NN in_IN case-control_JJ
          or_CC observational_NN studies_NNS ._. The_DT OR_NNP in_IN (_( 2_LS )_) describes_VBZ the_DT
          odds_NNS of_IN disease_NN or_CC no_DT disease_NN for_IN another_DT member_NN in_IN the_DT
          same_JJ cluster_NN ,_, given_VBN that_IN a_DT member_NN is_VBZ affected_VBN or_CC
          unaffected_JJ ._. We_PRP henceforth_NN refer_VBP to_TO this_DT OR_NNP as_IN '_POS OR_NNP for_IN
          clustering_VBG '_'' ._. Such_JJ ORs_NNP are_VBP commonly_RB used_VBN to_TO describe_VB
          familial_NN aggregation_NN of_IN disease_NN in_IN genetic_JJ studies_NNS [_NN 21_CD ]_NN
          ._. The_DT OR_NNP can_MD be_VB modeled_VBN for_IN subclasses_NNS or_CC sub-clusters_JJ
          within_IN the_DT main_JJ cluster_NN as_IN
          log_VB OR_NNP 
          jk_NN =_SYM γ_NN 
          z_SYM (_( 3_LS )_)
          Where_WRB z_SYM indicates_VBZ the_DT class_NN membership_NN of_IN the_DT (_( j_NN ,_, k_NN )_)
          pair_NN within_IN the_DT house_NN ._. For_IN example_NN ,_, if_IN we_PRP consider_VBP adults_NNS
          within_IN a_DT house_NN to_TO be_VB members_NNS of_IN class_NN '_'' a_NNP '_POS and_CC children_NNS to_TO
          be_VB members_NNS of_IN class_NN '_'' c_SYM '_POS ,_, then_RB log_VB (_( OR_NNP 
          jk_NN )_) =_SYM γ_NN 
          aa_NN ,_, γ_NN 
          cc_NN ,_, or_CC γ_NN 
          ac_NN depending_VBG on_IN whether_IN the_DT (_( j_NN ,_, k_NN )_)
          pair_NN are_VBP adults_NNS ,_, children_NNS ,_, or_CC an_DT adult-child_JJ pair_NN ._. From_IN
          equation_NN (_( 3_LS )_) we_PRP thus_RB obtain_VBP two_CD intra-class_JJ ORs_NNP namely_RB e_SYM
          γaaand_NN e_SYM γccfor_NN adults_NNS and_CC children_NNS respectively_RB and_CC one_CD
          inter-class_JJ OR_NNP namely_RB e_SYM γacbetween_NN adults_NNS and_CC children_NNS ._. A_DT
          significant_JJ γ_NN 
          aa_NN or_CC γ_NN 
          cc_NN is_VBZ suggestive_JJ of_IN clustering_VBG within_IN
          adults_NNS or_CC within_IN children_NNS ,_, whereas_IN a_DT significant_JJ γ_NN 
          ac_NN is_VBZ indicative_JJ of_IN the_DT existence_NN of_IN a_DT
          correlation_NN between_IN adults_NNS and_CC children_NNS ._. When_WRB z_SYM =_SYM 1_CD ,_,
          there_EX is_VBZ a_DT single_JJ class_NN and_CC the_DT equation_NN models_NNS a_DT
          constant_JJ log_NN odds_NNS across_IN all_PDT the_DT clusters_NNS ._. Estimates_NNS for_IN
          β_NN 's_POS and_CC γ_NN 's_POS are_NN obtained_VBN by_IN simultaneous_JJ estimation_NN of_IN
          the_DT parameters_NNS from_IN equations_NNS (_( 1_LS )_) and_CC (_( 3_LS )_) ,_, thereby_RB
          adjusting_VBG the_DT ORs_NNP for_IN covariates_NNS introduced_VBN in_IN (_( 1_LS )_) ._.
          Further_RB details_NNS on_IN the_DT formulation_NN ,_, estimation_NN methods_NNS ,_,
          features_NNS of_IN the_DT model_NN ,_, and_CC properties_NNS of_IN the_DT estimators_NNS
          have_VBP been_VBN published_VBN elsewhere_RB [_NN 18_CD 19_CD 20_CD ]_NN ._.
          To_TO model_VB sub-groups_JJ of_IN high_JJ and_CC low_JJ risk_NN groups_NNS within_IN
          houses_NNS ,_, we_PRP chose_VBD an_DT age_NN cutoff_NN of_IN 15_CD years_NNS based_VBN on_IN an_DT
          examination_NN of_IN the_DT age-specific_JJ prevalence_NN within_IN our_PRP$
          study_NN and_CC based_VBN on_IN reports_NNS stating_VBG that_DT parenteral_NN
          treatment_NN of_IN schistosomiasis_NNS was_VBD stopped_VBN between_IN 1982_CD and_CC
          1986_CD ,_, with_IN the_DT introduction_NN of_IN praziquintal_NN ,_, an_DT oral_JJ drug_NN
          used_VBN to_TO treat_VB the_DT disease_NN [_NN 22_CD ]_NN ._. Further_RB ,_, children_NNS
          under_IN 5_CD years_NNS of_IN age_NN were_VBD not_RB eligible_JJ for_IN receiving_VBG
          injections_NNS during_IN the_DT campaigns_NNS ._. Since_IN children_NNS born_VBN in_IN
          1981_CD would_MD have_VB been_VBN 14_CD years_NNS of_IN age_NN at_IN the_DT time_NN of_IN our_PRP$
          1995_CD HCV_NNP study_NN ,_, it_PRP can_MD be_VB safely_RB assumed_VBN that_IN they_PRP were_VBD
          not_RB present_JJ at_IN the_DT time_NN of_IN the_DT schistosomiasis_NNS campaigns_NNS ._.
          This_DT age_NN cutoff_NN has_VBZ also_RB been_VBN used_VBN in_IN other_JJ studies_NNS [_NN 13_CD
          ]_NN ._.
          We_PRP conducted_VBD our_PRP$ analysis_NN using_VBG the_DT ALR_NNP implementation_NN
          of_IN GEE_NNP in_IN SAS_NNP V_NNP 8_CD ._. 02_CD (_( SAS_NNP Institute_NNP Inc_NNP ._. ,_, Cary_NNP ,_, NC_NNP )_) ._. Since_IN
          we_PRP assume_VBP that_IN the_DT parenteral_NN treatment_NN for_IN
          schistosomiasis_NNS in_IN the_DT campaigns_NNS for_IN the_DT entire_JJ house_NN
          occurred_VBD around_IN the_DT same_JJ time_NN ,_, to_TO model_VB the_DT correlation_NN
          between_IN the_DT members_NNS of_IN the_DT house_NN ,_, ordering_VBG of_IN individuals_NNS
          within_IN the_DT house_NN (_( cluster_NN )_) is_VBZ not_RB relevant_JJ ._. Hence_RB ,_, to_TO
          model_VB the_DT OR_NNP for_IN clustering_VBG of_IN schistosmiasis_NNS treatment_NN
          in_IN the_DT house_NN ,_, an_DT exchangeable_JJ log_NN odds_NNS ratio_NN was_VBD assumed_VBN ._.
          With_IN an_DT exchangeable_JJ log_NN odds_NNS ratio_NN ,_, a_DT constant_JJ OR_NNP for_IN
          clustering_VBG is_VBZ assumed_VBN for_IN all_DT houses_NNS ._. To_TO estimate_VB the_DT
          degree_NN of_IN clustering_VBG of_IN HCV_NNP infections_NNS ,_, a_DT history_NN of_IN
          parenteral_NN treatment_NN of_IN schistosomiasis_NNS in_IN the_DT house_NN was_VBD
          considered_VBN to_TO be_VB a_DT blocking_VBG factor_NN ._. Separate_NNP log_VB odds_NNS
          ratios_NNS were_VBD estimated_VBN for_IN each_DT block_NN with_IN the_DT assumption_NN
          that_IN the_DT log_NN odds_NNS ratios_NNS are_VBP constant_JJ within_IN each_DT
          block_NN ._.
        
      
      
        Results_NNS
        The_DT study_NN sample_NN contained_VBD 910_CD age_NN eligible_JJ individuals_NNS
        residing_VBG in_IN 168_CD houses_NNS ._. Of_IN these_DT ,_, 810_CD (_( 88_CD %_NN )_) agreed_VBD to_TO
        participate_VB in_IN the_DT study_NN and_CC provided_VBN blood_NN samples_NNS ._. The_DT
        number_NN of_IN participants_NNS within_IN these_DT houses_NNS ranged_VBD from_IN 1_CD to_TO
        20_CD members_NNS with_IN a_DT median_JJ (_( inter-quartile_JJ range_NN )_) of_IN 4_CD (_( 2_CD -_:
        6_CD )_) members_NNS ._. Anti-_NNP HCV_NNP antibodies_NNS were_VBD evaluated_VBN for_IN 796_CD
        (_( 98_CD %_NN )_) of_IN the_DT blood_NN samples_NNS collected_VBN ._. A_DT total_NN of_IN 321_CD (_( 40_CD %_NN )_)
        subjects_NNS were_VBD sero-reactive_JJ to_TO HCV_NNP ._. Individuals_NNS positive_JJ
        for_IN HCV_NNP were_VBD significantly_RB older_JJR than_IN those_DT who_WP were_VBD
        negative_JJ (_( p_NN <_NN ._. 001_CD )_) ._. Other_JJ variables_NNS measured_VBN at_IN
        baseline_NN were_VBD comparable_JJ for_IN the_DT two_CD groups_NNS ._. Although_IN not_RB
        statistically_RB significant_JJ ,_, HCV_NNP seropositive_JJ individuals_NNS
        were_VBD more_RBR frequently_RB males_NNS and_CC of_IN low_JJ socio-economic_JJ status_NN
        (_( table_NN 1_LS )_) ._. Age_NNP specific_JJ HCV_NNP positive_JJ prevalence_NN rates_NNS
        increase_VBP around_IN 15_CD years_NNS of_IN age_NN suggesting_VBG the_DT possibility_NN
        of_IN a_DT cohort_NN effect_NN (_( table_NN 2_LS )_) ._. The_DT sero-prevalence_JJ of_IN
        anti-_NN HCV_NNP antibodies_NNS was_VBD 11_CD %_NN (_( 95_CD %_NN CI_NNP :_: 6_CD %_NN -_: 16_CD %_NN )_) for_IN children_NNS
        under_IN 15_CD years_NNS of_IN age_NN compared_VBN to_TO 47_CD %_NN (_( 95_CD %_NN CI_NNP :_: 43_CD %_NN -_: 51_CD %_NN )_)
        for_IN those_DT 15_CD years_NNS or_CC older_JJR (_( p_NN <_NN ._. 0001_CD )_) ._.
        Fifty_NNP adults_NNS reported_VBD receiving_VBG injections_NNS for_IN the_DT
        treatment_NN of_IN schistosomiasis_NNS ._. Houses_NNP in_IN which_WDT an_DT adult_NN
        member_NN reported_VBD receiving_VBG parenteral_NN treatment_NN were_VBD more_RBR
        likely_JJ to_TO have_VB other_JJ adult_NN members_NNS with_IN histories_NNS of_IN
        parenteral_NN treatment_NN for_IN schistosomiasis_NNS ._. The_DT OR_NNP for_IN
        clustering_VBG of_IN individuals_NNS receiving_VBG parenteral_NN treatment_NN
        was_VBD 2_CD ._. 44_CD (_( 95_CD %_NN CI_NNP :_: 1_CD ._. 47_CD -_: 4_CD ._. 06_CD ;_: p_NN <_NN 0_CD ._. 001_CD )_) ,_, suggesting_VBG
        that_IN past_JJ participation_NN in_IN the_DT treatment_NN campaigns_NNS tended_VBD
        to_TO cluster_NN within_IN houses_NNS ._.
        Among_IN the_DT 746_CD individuals_NNS who_WP reported_VBD no_DT history_NN of_IN
        schistosomiasis_NNS or_CC no_DT parenteral_NN treatment_NN for_IN diagnosed_VBN
        schistosomiasis_NNS ,_, the_DT prevalence_NN of_IN HCV_NNP was_VBD 38_CD %_NN compared_VBN to_TO
        68_CD %_NN for_IN the_DT 50_CD individuals_NNS who_WP reported_VBD receiving_VBG the_DT
        treatment_NN (_( p_NN <_NN ._. 0001_CD )_) ._. Examination_NNP of_IN the_DT degree_NN of_IN
        clustering_VBG of_IN HCV_NNP infections_NNS among_IN houses_NNS with_IN members_NNS that_WDT
        received_JJ parenteral_NN treatment_NN indicated_VBD that_IN there_EX was_VBD a_DT
        significant_JJ degree_NN of_IN clustering_VBG of_IN HCV_NNP infections_NNS in_IN such_JJ
        houses_NNS ._. After_IN adjusting_VBG for_IN individual_JJ level_NN effects_NNS of_IN age_NN
        and_CC gender_NN ,_, and_CC household_NN characteristics_NNS such_JJ as_IN
        socio-economic_JJ status_NN and_CC risk_NN group_NN based_VBN on_IN eligibility_NN
        for_IN participation_NN in_IN the_DT schistosomiasis_NNS treatment_NN
        campaigns_NNS ,_, all_DT of_IN which_WDT were_VBD significant_JJ confounding_VBG
        variables_NNS ,_, the_DT OR_NNP for_IN clustering_VBG of_IN HCV_NNP infections_NNS was_VBD 1_CD ._. 76_CD
        (_( 95_CD %_NN CI_NNP :_: 1_CD ._. 05_CD -_: 2_CD ._. 95_CD ;_: p_NN <_NN ._. 05_CD )_) (_( table_NN 3_LS )_) ._. In_IN contrast_NN ,_,
        the_DT OR_NNP for_IN clustering_VBG of_IN HCV_NNP infections_NNS among_IN houses_NNS in_IN
        which_WDT no_DT member_NN reported_VBD a_DT history_NN of_IN parenteral_NN treatment_NN
        for_IN a_DT past_JJ schistosomiasis_NNS infection_NN was_VBD 1_CD ._. 37_CD (_( 95_CD %_NN CI_NNP :_: 0_CD ._. 92_CD
        -_: 2_CD ._. 05_CD ;_: p_NN =_SYM 0_CD ._. 12_CD )_) ._. If_IN we_PRP inappropriately_RB used_VBD logistic_JJ
        regression_NN and_CC treated_VBD all_DT participants_NNS to_TO be_VB independent_JJ
        of_IN each_DT other_JJ ,_, the_DT odds_NNS of_IN HCV_NNP infection_NN among_IN members_NNS
        reporting_VBG previous_JJ parenteral_NN schistosomiasis_NNS treatment_NN
        compared_VBN to_TO those_DT who_WP did_VBD not_RB ,_, after_IN adjusting_VBG for_IN the_DT same_JJ
        confounding_VBG variables_NNS ,_, was_VBD 1_CD ._. 55_CD (_( 95_CD %_NN CI_NNP :_: 0_CD ._. 81_CD -_: 2_CD ._. 98_CD ;_: p_NN =_SYM
        0_CD ._. 19_CD )_) ._.
      
      
        Discussion_NNP
        Our_PRP$ analysis_NN reveals_VBZ that_IN there_EX is_VBZ significant_JJ amount_NN of_IN
        clustering_VBG of_IN HCV_NNP infections_NNS within_IN houses_NNS of_IN the_DT study_NN
        village_NN and_CC that_IN the_DT infections_NNS are_VBP not_RB distributed_VBN
        uniformly_RB across_IN the_DT village_NN ._. We_PRP also_RB demonstrate_VBP that_IN some_DT
        households_NNS were_VBD more_RBR likely_JJ to_TO have_VB participated_VBN in_IN the_DT
        schistosomiasis_NNS treatment_NN campaigns_NNS compared_VBN to_TO others_NNS and_CC
        that_IN the_DT clustering_VBG of_IN HCV_NNP infections_NNS were_VBD more_RBR likely_JJ
        among_IN the_DT households_NNS that_WDT participated_VBD in_IN the_DT treatment_NN
        campaigns_NNS ._. In_IN the_DT general_JJ population_NN ,_, based_VBN on_IN the_DT time_NN
        period_NN during_IN which_WDT the_DT treatment_NN campaigns_NNS were_VBD conducted_VBN
        and_CC the_DT ensuing_VBG age_NN distribution_NN of_IN the_DT HCV_NNP infections_NNS
        obtained_VBN from_IN multiple_JJ cross-sectional_JJ surveys_NNS ,_, a_DT temporal_JJ
        and_CC possible_JJ causal_NN relationship_NN between_IN these_DT two_CD events_NNS
        has_VBZ been_VBN suggested_VBN [_NN 13_CD ]_NN ._. Our_PRP$ study_NN adds_VBZ to_TO this_DT finding_VBG
        by_IN studying_VBG these_DT two_CD events_NNS within_IN the_DT same_JJ population_NN ,_,
        thus_RB providing_VBG further_JJ evidence_NN that_IN the_DT spread_NN of_IN HCV_NNP in_IN
        the_DT Nile_NNP Delta_NNP region_NN was_VBD associated_VBN with_IN the_DT
        schistosomiasis_NNS treatment_NN campaign_NN ._.
        The_DT observation_NN that_IN households_NNS were_VBD more_RBR likely_JJ to_TO have_VB
        participated_VBN in_IN the_DT treatment_NN campaign_NN if_IN any_DT member_NN within_IN
        the_DT house_NN participated_VBD in_IN the_DT campaign_NN is_VBZ corroborated_JJ by_IN
        the_DT manner_NN in_IN which_WDT the_DT treatment_NN campaigns_NNS were_VBD conducted_VBN ._.
        Unlike_IN mass_NN campaigns_NNS conducted_VBN for_IN vaccinations_NNS ,_, where_WRB
        house-to-house_JJ visits_NNS are_VBP made_VBN and_CC residents_NNS are_VBP immunized_JJ ,_,
        the_DT treatment_NN campaigns_NNS were_VBD conducted_VBN at_IN centralized_VBN
        health_NN care_NN facilities_NNS such_JJ as_IN hospitals_NNS and_CC clinics_NNS ._. In_IN
        some_DT instances_NNS ,_, these_DT clinics_NNS were_VBD rolling_VBG clinics_NNS
        established_VBN temporarily_RB at_IN the_DT villages_NNS ._. This_DT situation_NN
        makes_VBZ it_PRP likely_JJ that_IN entire_JJ households_NNS rather_RB than_IN random_JJ
        individuals_NNS would_MD have_VB visited_VBN the_DT clinics_NNS based_VBN on_IN factors_NNS
        such_JJ as_IN proximity_NN ,_, risk_NN of_IN schistosomiasis_NNS infection_NN to_TO the_DT
        household_NN ,_, and_CC socio-economic_JJ status_NN ._. Indeed_RB ,_, our_PRP$ analysis_NN
        finds_VBZ that_IN socio-economic_JJ status_NN of_IN a_DT house_NN was_VBD strongly_RB
        predictive_JJ of_IN whether_IN an_DT individual_JJ tests_NNS positive_JJ for_IN HCV_NNP ,_,
        after_IN adjusting_VBG for_IN the_DT effects_NNS of_IN clustering_VBG ._.
        Potential_JJ limitations_NNS of_IN this_DT study_NN need_VBP to_TO be_VB
        mentioned_VBN ._. Since_IN reports_NNS of_IN receiving_VBG injections_NNS for_IN
        treatment_NN of_IN schistosomiasis_NNS were_VBD by_IN recall_NN ,_, it_PRP is_VBZ possible_JJ
        that_IN inaccuracies_NNS in_IN the_DT recall_NN might_MD have_VB biased_VBN the_DT
        results_NNS of_IN the_DT study_NN ._. Additionally_RB ,_, it_PRP is_VBZ possible_JJ that_IN a_DT
        report_NN by_IN one_CD member_NN of_IN the_DT family_NN potentially_RB influences_VBZ
        the_DT response_NN of_IN another_DT family_NN member_NN during_IN the_DT interview_NN
        process_NN ._. Such_JJ related_VBN responses_NNS will_MD artificially_RB tend_VB to_TO
        show_VB clustering_VBG of_IN participation_NN in_IN the_DT treatment_NN campaigns_NNS
        within_IN the_DT houses_NNS ._. However_RB ,_, since_IN testing_NN of_IN sera_NN for_IN HCV_NNP
        antibodies_NNS for_IN the_DT members_NNS of_IN the_DT family_NN was_VBD done_VBN without_IN
        knowledge_NN of_IN which_WDT sera_NN belonged_VBD to_TO which_WDT family_NN ,_, and_CC since_IN
        clustering_VBG of_IN HCV_NNP infections_NNS was_VBD observed_VBN within_IN families_NNS
        independent_JJ of_IN the_DT participation_NN in_IN the_DT treatment_NN
        campaigns_NNS ,_, it_PRP is_VBZ unlikely_JJ that_IN the_DT clustering_VBG of_IN the_DT
        individuals_NNS '_POS participation_NN in_IN the_DT treatment_NN campaigns_NNS were_VBD
        solely_RB due_JJ to_TO biased_VBN reporting_VBG since_IN there_EX is_VBZ an_DT 
        a_DT priori_FW reason_NN to_TO believe_VB that_IN such_JJ
        clustering_VBG is_VBZ possible_JJ on_IN the_DT basis_NN of_IN the_DT manner_NN in_IN which_WDT
        the_DT campaigns_NNS were_VBD conducted_VBN ._. It_PRP could_MD be_VB stated_VBN that_DT
        familial_NN clustering_VBG of_IN HCV_NNP infections_NNS may_MD be_VB due_JJ to_TO other_JJ
        factors_NNS or_CC behaviors_NNS that_WDT are_VBP related_VBN to_TO an_DT increased_VBN risk_NN
        of_IN schistosomiasis_NNS as_RB well_RB as_IN an_DT increased_VBN risk_NN of_IN HCV_NNP
        infections_NNS ._. Alternatively_RB ,_, certain_JJ household_NN behaviors_NNS such_JJ
        as_IN health_NN care_NN practices_NNS or_CC tendency_NN to_TO visit_VB providers_NNS who_WP
        use_VBP unsafe_JJ treatment_NN methods_NNS ,_, could_MD also_RB result_VB in_IN
        clustering_VBG of_IN HCV_NNP infections_NNS within_IN the_DT families_NNS ._. If_IN this_DT
        were_VBD true_JJ and_CC was_VBD the_DT sole_JJ explanation_NN for_IN the_DT clustering_VBG
        of_IN HCV_NNP infections_NNS within_IN the_DT household_NN ,_, we_PRP would_MD expect_VB to_TO
        see_VB HCV_NNP infections_NNS in_IN the_DT younger_JJR children_NNS too_RB who_WP were_VBD not_RB
        present_JJ in_IN the_DT households_NNS at_IN the_DT time_NN of_IN the_DT treatment_NN
        campaigns_NNS within_IN such_JJ families_NNS ._. However_RB ,_, our_PRP$ previous_JJ work_NN
        in_IN this_DT village_NN found_VBD HCV_NNP infections_NNS among_IN children_NNS less_JJR
        than_IN 10_CD years_NNS of_IN age_NN to_TO be_VB extremely_RB rare_JJ ,_, thus_RB making_VBG it_PRP
        less_RBR likely_JJ that_IN unmeasured_JJ factors_NNS might_MD be_VB influencing_VBG
        this_DT association_NN ._.
        Despite_IN the_DT use_NN of_IN oral_JJ drugs_NNS for_IN the_DT treatment_NN of_IN
        schistosomiasis_NNS during_IN the_DT past_JJ two_CD decades_NNS ,_, HCV_NNP antibodies_NNS
        were_VBD detected_VBN in_IN some_DT children_NNS below_IN 15_CD years_NNS of_IN age_NN ._.
        Vertical_NNP transmission_NN of_IN HCV_NNP from_IN infected_JJ mother_NN to_TO infant_NN
        occurs_VBZ in_IN approximately_RB 5_CD %_NN of_IN HCV_NNP infected_JJ mothers_NNS and_CC is_VBZ
        reported_VBN to_TO increase_VB with_IN increasing_VBG viral_JJ loads_NNS [_NN 23_CD ]_NN ._.
        Prospective_JJ studies_NNS could_MD help_VB determine_VB the_DT relative_JJ
        contribution_NN of_IN vertical_JJ and_CC horizontal_NN transmission_NN of_IN HCV_NNP
        infections_NNS observed_VBD in_IN these_DT children_NNS ._.
        Most_JJS previous_JJ studies_NNS that_WDT have_VBP that_WDT have_VBP found_VBN
        associations_NNS between_IN histories_NNS of_IN schistosomiasis_NNS and_CC HCV_NNP
        have_VBP either_CC been_VBN designed_VBN as_IN surveys_NNS or_CC have_VBP used_VBN ecologic_JJ
        associations_NNS ._. While_IN ecologic_JJ associations_NNS are_VBP very_RB useful_JJ
        for_IN generating_NN hypotheses_NNS ,_, one_PRP should_MD be_VB cautious_JJ in_IN trying_VBG
        to_TO make_VB individual_JJ level_NN inferences_NNS from_IN population_NN based_VBD
        observations_NNS because_IN of_IN the_DT multiple_JJ sources_NNS of_IN biases_NNS
        associated_VBN with_IN such_JJ study_NN designs_NNS [_NN 24_CD ]_NN ._. After_IN using_VBG the_DT
        appropriate_JJ analytic_JJ methods_NNS ,_, our_PRP$ results_NNS provide_VBP further_JJ
        evidence_NN for_IN an_DT association_NN between_IN the_DT parenteral_NN
        schistosomiasis_NNS treatment_NN campaigns_NNS and_CC the_DT transmission_NN of_IN
        HCV_NNP infections_NNS in_IN Egypt_NNP ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        MR_NNP conceptualized_JJ the_DT problem_NN ,_, wrote_VBD the_DT manuscript_NN and_CC
        conducted_VBD the_DT analysis_NN ._. MD_NNP and_CC ND_NNP collected_VBD the_DT data_NNS and_CC
        performed_VBD the_DT laboratory_NN analysis_NN ._. AN_DT ,_, ES_NNP ,_, JC_NNP and_CC RE_NNP
        participated_VBD in_IN the_DT design_NN ,_, conduct_NN ,_, and_CC monitoring_NN of_IN the_DT
        study_NN assisted_VBN in_IN the_DT preparation_NN of_IN the_DT manuscript_NN ._. All_DT
        authors_NNS have_VBP read_VBN and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
